Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis

Cancer Medicine

Volumn 5, Issue 6, 2016, Pages 1055-1065

  Jiang, Tao ^a   Min, Weijie ^b   Li, Yanan ^b   Yue, Zhijian ^b   Wu, Chunyan ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Brain metastases; EGFR TKI; meta analysis; non small cell lung cancer; radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; TEMOZOLOMIDE;

ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRY SKIN; DYSPNEA; FATIGUE; HEADACHE; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84991522367     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.673     Document Type: Article

References (54)

1. Zhang, J., J. Yu, X. Sun, and X. Meng. 2014. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer. Cancer Lett. 351:6–12.
2. Lombardi, G., A. L. Di Stefano, P. Farina, V. Zagonel, and E. Tabouret. 2014. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat. Rev. 40:951–959.
3. Adamo, V., T. Franchina, B. Adamo, G. Scandurra, and A. Scimone. 2006. Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. Ann. Oncol. 17(Suppl 2):ii73–ii75.
4. Eichler, A. F., E. Chung, D. P. Kodack, J. S. Loeffler, D. Fukumura, and R. K. Jain. 2011. The biology of brain metastases-translation to new therapies. Nat. Rev. Clin. Oncol. 8:344–356.
5. Berger, L. A., H. Riesenberg, C. Bokemeyer, and D. Atanackovic. 2013. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80:242–248.
6. Sperduto, P. W., N. Kased, D. Roberge, Z. Xu, R. Shanley, X. Luo, et al. 2012. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30:419–425.
7. Scoccianti, S., and U. Ricardi. 2012. Treatment of brain metastases: review of phase III randomized controlled trials. Radiother. Oncol. 102:168–179.
8. Tsao, M. N., D. Rades, A. Wirth, S. S. Lo, B. L. Danielson, L. E. Gaspar, et al. 2012. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract. Radiat. Oncol. 2:210–225.
9. Mok, T. S., Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, et al. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:947–957.
10. Zhou, C., Y. L. Wu, G. Chen, J. Feng, X. Q. Liu, C. Wang, et al. 2011. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742.
11. Rosell, R., E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, et al. 2012. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246.
12. Zhuang, H., J. Wang, L. Zhao, Z. Yuan, and P. Wang. 2013. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int. J. Cancer 133:2277–2283.
13. Chinnaiyan, P., S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, et al. 2005. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65:3328–3335.
14. Weber, B., M. Winterdahl, A. Memon, B. S. Sorensen, S. Keiding, L. Sorensen, et al. 2011. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J. Thorac. Oncol. 6:1287–1289.
15. Cai, L., J. F. Zhu, X. W. Zhang, S. X. Lin, X. D. Su, P. Lin, et al. 2014. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J. Neurooncol. 120:423–430.
16. Wang, F., F. Ning, C. Liu, Y. Hao, L. Li, Z. Yu, et al. 2015. Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer. Cell Biochem. Biophys. 71:1261–1265.
17. Zhuang, H., Z. Yuan, J. Wang, L. Zhao, Q. Pang, and P. Wang. 2013. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des. Devel. Ther. 7:1179–1186.
18. Lee, S. M., C. R. Lewanski, N. Counsell, C. Ottensmeier, A. Bates, N. Patel, et al. 2014. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J. Natl Cancer Inst. 106:1–7.
19. Sperduto, P. W., M. Wang, H. I. Robins, M. C. Schell, M. Werner-Wasik, R. Komaki, et al. 2013. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int. J. Radiat. Oncol. Biol. Phys. 85:1312–1318.
20. Luo, S., L. Chen, X. Chen, and X. Xie. 2015. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget 6:16725–16734.
21. Tierney, J. F., L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes. 2007. Practical methods for incorporating summary time-to event data into meta-analysis. Eur. J. Cancer 8:16.
22. Pesce, G. A., D. Klingbiel, K. Ribi, A. Zouhair, R. von Moos, M. Schlaeppi, et al. 2012. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur. J. Cancer 48:377–384.
23. Zeng, Y. D., L. Zhang, H. Liao, Y. Liang, F. Xu, J. L. Liu, et al. 2012. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac. J. Cancer Prev. 13:909–914.
24. Cai, Y., J. Y. Wang, and H. Liu. 2013. Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac. J. Cancer Prev. 14:5699–5703.
25. Fan, Y., Z. Huang, L. Fang, L. Miu, N. Lin, L. Gong, et al. 2013. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco. Targets Ther. 6:1789–1803.
26. Fu, H., X. L. Zhang, Y. Xiao, X. J. Liu, C. Long, andY. D. Hu. 2012. Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases. Zhonghua Yi Xue Za Zhi 92:524–527.
27. Di Zhou, X. X., H. Xie, X. Ma, and Y. Bai. 2013. Therapeutic effects of whole brain radiotherapy with targeted therapy and concomitant chemo-radiotherapy in treatment of non-small cell lung cancer with brain metastasis. J. Shanghai Jiaotong University (Medical Science) 33:480–484.
28. Jingsheng Chen, Y. W., G. Chen, and H. Zhong. 2015. Clinical research of gefitinib plus radiotherapy in lung cancer patients with brain metastasis. Intern. Med. 10:38–40.
29. Liu, P. 2013. The effect of epidermal growth factor receptor tyrosine kinase inhibitors combined with radiotherapy in non-small cell lung cancer patients with brain metastasis. J. Chin. Pract. Diagn. Ther. 27:693–694.
30. Liu, Z. 2015. Effect of whole brain radiotherapy combined with targeted therapy and concurrent chemotherapy in the treatment of non-small cell lung cancer. Chin. Foreign Med. Res. 13:13–14.
31. Wu, T. A., D. R. Liu, Z. H. Wang, and Y. Peng. 2012. Effects of gefitinib combined with whole brain radiation on brain metastasis from non-small-cell lung cancer. Chin. J. Gen. Pract. 10:893–895.
32. Langer, C. J., and M. P. Mehta. 2005. Current management of brain metastases, with a focus on systemic options. J. Clin. Oncol. 23:6207–6219.
33. Khuntia, D., P. Brown, J. Li, and M. P. Mehta. 2006. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol. 24:1295–1304.
34. Chua, D., M. Krzakowski, C. Chouaid, M. G. Pallotta, J. I. Martinez, M. Gottfried, et al. 2010. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin. Lung Cancer 11:176–181.
35. Guerrieri, M., K. Wong, G. Ryan, M. Millward, G. Quong, and D. L. Ball. 2004. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46:107–111.
36. Cortes, J., J. Rodriguez, J. M. Aramendia, E. Salgado, A. Gurpide, J. Garcia-Foncillas, et al. 2003. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64:28–35.
37. Verger, E., M. Gil, R. Yaya, N. Vinolas, S. Villa, T. Pujol, et al. 2005. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 61:185–191.
38. Broniscer, A., J. C. Panetta, M. O'Shaughnessy, C. Fraga, F. Bai, M. J. Krasin, et al. 2007. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin. Cancer Res. 13:1511–1515.
39. Togashi, Y., K. Masago, M. Fukudo, T. Terada, S. Fujita, K. Irisa, et al. 2010. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J. Thorac. Oncol. 5:950–955.
40. Togashi, Y., K. Masago, M. Fukudo, Y. Tsuchido, C. Okuda, Y. H. Kim, et al. 2011. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother. Pharmacol. 68:1089–1092.
41. Porta, R., J. M. Sanchez-Torres, L. Paz-Ares, B. Massuti, N. Reguart, C. Mayo, et al. 2011. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur. Respir. J. 37:624–631.
42. Matsumoto, S., K. Takahashi, R. Iwakawa, Y. Matsuno, Y. Nakanishi, T. Kohno, et al. 2006. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 119:1491–1494.
43. Gow, C. H., Y. L. Chang, Y. C. Hsu, M. F. Tsai, C. T. Wu, C. J. Yu, et al. 2009. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 20:696–702.
44. Huang, S. F., H. P. Liu, L. H. Li, Y. C. Ku, Y. N. Fu, H. Y. Tsai, et al. 2004. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10:8195–8203.
45. Wu, Y. L., W. Z. Zhong, L. Y. Li, X. T. Zhang, L. Zhang, C. C. Zhou, et al. 2007. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J. Thorac. Oncol. 2:430–439.
46. Sun, M., C. Behrens, L. Feng, N. Ozburn, X. Tang, G. Yin, et al. 2009. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin. Cancer Res. 15:4829–4837.
47. Daniele, L., P. Cassoni, E. Bacillo, S. Cappia, L. Righi, M. Volante, et al. 2009. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J. Thorac. Oncol. 4:684–688.
48. Burel-Vandenbos, F., D. Ambrosetti, M. Coutts, and F. Pedeutour. 2013. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J. Neurooncol. 111:1–10.
49. Whitsett, T. G., L. J. Inge, H. D. Dhruv, P. Y. Cheung, G. J. Weiss, R. M. Bremner, et al. 2013. Molecular determinants of lung cancer metastasis to the central nervous system. Transl. Lung Cancer Res. 2:273–283.
50. Nguyen, D. X., A. C. Chiang, X. H. Zhang, J. Y. Kim, M. G. Kris, M. Ladanyi, et al. 2009. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138:51–62.
51. Valiente, M., A. C. Obenauf, X. Jin, Q. Chen, X. H. Zhang, D. J. Lee, et al. 2014. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002–1016.
52. Lin, C. Y., H. J. Chen, C. C. Huang, L. C. Lai, T. P. Lu, G. C. Tseng, et al. 2014. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 74:5229–5243.
53. Renaud, S., M. Schaeffer, A. C. Voegeli, M. Legrain, E. Guerin, N. Meyer, et al. 2016. Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. Future Oncol 12:59–70.
54. Wang, M., A. M. Kern, M. Hulskotter, P. Greninger, A. Singh, Y. Pan, et al. 2014. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 74:2825–2834.